A worldwide adverse drug event monitoring and management system is described. Two subsidiaries encompassing over two dozen regional offices are linked by a FAX network. A common format is used for central collection and distribution of information. Each regional office reformats information to comply with regulatory reporting requirements. Surveillance methods are described, coordination problems are outlined, and sources of bias in assessing incidence changes are discussed
TealTWDimmigAL. Adverse drug experience management. A brief review of the McNeil Pharmaceutical system. Drug Inf J.1985;19:17–25.
2.
MichalakRA. Investigational adverse experience reporting. Drug Inf J.1987;21:277–282.
3.
NissmanEF. The use of COSTART at Burroughs Wellcome Company. Drug Inf J.1987;21:295–298.
4.
SchneiweissF. Adverse reaction thesauri used in the pharmaceutical industry. Drug Inf J.1987;21:299–302.
5.
GoldsmithDIYenCCGreenbergBP. A comprehensive system for international pharmaceutical company monitoring of adverse drug reactions. Drug Inf J.1986;20:305–310.
6.
WallanderAMPalmerLS. A monitoring system for adverse drug experiences in a pharmaceutical company: the integration of pre- and postmarketing data. Drug Inf J.1986;20:225–235.
7.
HostelleyL. Reporting and tracking spontaneous adverse experience reports via a computer database. Drug Inf J.1989;23:171–177.
8.
HermanRL. System integration of an adverse experience thesaurus-experience with a new computer methodology. Drug Inf J.1986;20:351–355.
9.
StreichenweinSM. Communication of ADR information: Views from the pharmaceutical industry. Drug Inf J.1985;19:367–370.
10.
StreichenweinSM. Actual aspects of data integration-a view from an international company. Drug Inf J.1986;20:301–304.
11.
TalbotJCC. Database management and reporting systems- foreign-based companies: The Glaxo approach. Drug Inf J.1989;23:189–196.
12.
TilsonHH. Discussion panel: Database management and reporting systems of foreign-based companies. Drug Inf J.1989;23:197–202.
13.
MaskellLJE. Wellcome group computer-based system for adverse drug reaction report management. Drug Inf J.1989;23:203–210.
14.
SerradellJBjornsonDCHartzema. Drug utilization study methodologies: National and international perspectives. Drug Intell Clin Pharm1987;21:994–1001.
15.
EldavitchSA. Postmarketing surveillance methodologies. Drug Intell Clin Pharm1988;22:68–78.
16.
MichelDJDahlJMCampbellHE. Postmarketing surveillance of drugs: An overview. J Pharm Pract1989;2:231–238.
